13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q1 2025. See the latest, Q2 2026 →

Reported value

$1.58B

−8.2% on the quarter before

Positions

3 new · 3 sold out

Top 10

87.3%

of the value

Est. gain

−$193.9M

on stocks held all quarter

Est. return

−13.8%

on those stocks since Q4 2024

Filed

May 2, 2025

On SEC EDGAR ↗

Positions as of Mar 31, 2025, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2024. Striped tiles are options.

Freshworks Inc15%

Arm Holdings Plc13%

Ast Spacemobile Inc13%

Revolution Medicines Inc9.3%

Metsera Inc8.6%

Gitlab Inc8.1%

Planet Labs Pbc6.8%

Tempus AI4.7%UiPath4.6%

Dexcom Inc4.5%

Verve Therapeutics Inc3.6%

Prime Medicine Inc1.9%

Maze Therapeutics Inc1.7%

CrowdStrike1.7%

0.8%

Freshworks Inc15%

Arm Holdings Plc13%

Ast Spacemobile Inc13%

Revolution Medicines Inc9.3%

Metsera Inc8.6%

Gitlab Inc8.1%

Planet Labs Pbc6.8%

Tempus AI4.7%UiPath4.6%

Dexcom Inc4.5%

Verve Therapeutics Inc3.6%

Prime Medicine Inc1.9%

Maze Therapeutics Inc1.7%

CrowdStrike1.7%

0.8%

Largest buys

Since Q4 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Ast Spacemobile Inc~$203.4MNew · 0.0% → 12.9%+8,943,486 shares
Metsera Inc~$135.1MNew · 0.0% → 8.6%+4,961,744 shares
Maze Therapeutics Inc~$26.6MNew · 0.0% → 1.7%+2,412,471 shares

Largest sells

Since Q4 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Gitlab Inc~$158.2MCut · 20.0% → 8.1%−3,366,526 shares
CrowdStrike~$124.7MCut · 8.5% → 1.7%−353,665 shares
Benson Hill Inc~$864,111Sold out · 0.1% → 0.0%−438,635 shares
Cue Health Inc~$0.00Sold out · 0.0% → 0.0%−27,000 shares
Invitae Corp~$0.00Sold out · 0.0% → 0.0%−235,606 shares

Holdings

As of Mar 31, 2025. Changes are in shares against Dec 31, 2024, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Freshworks IncCLASS A COM · shares 0% · price −12.7%	14.5%	15.3%	$228.7M	16.2M	0%	$14.11	$16.17	−12.7%	−$33.4M
2	Arm Holdings PlcSPONSORED ADS · shares 0% · price −13.4%	13.3%	14.1%	$209.4M	2.0M	0%	$106.79	$123.36	−13.4%	−$32.5M
3	Ast Spacemobile IncCOM CL A · shares New	12.9%	—	$203.4M	8.9M	New	$22.74	—	—	—
4	Revolution Medicines IncCOM · shares 0% · price −19.2%	9.3%	10.5%	$146.2M	4.1M	0%	$35.36	$43.74	−19.2%	−$34.6M
5	Metsera IncCOM · shares New	8.6%	—	$135.1M	5.0M	New	$27.22	—	—	—
6	Gitlab IncCLASS A COM · shares −55% · price −16.6%	8.1%	20.0%	$128.1M	2.7M	−55%	$47.00	$56.35	−16.6%	−$25.5M
7	Planet Labs PbcCOM CL A · shares 0% · price −16.3%	6.8%	7.5%	$108.0M	31.9M	0%	$3.38	$4.04	−16.3%	−$21.1M
8	Tempus AICL A · shares 0% · price +42.9%	4.7%	3.0%	$74.8M	1.6M	0%	$48.24	$33.76	+42.9%	+$22.5M
9	UiPathCL A · shares 0% · price −19.0%	4.6%	5.2%	$72.5M	7.0M	0%	$10.30	$12.71	−19.0%	−$17.0M
10	Dexcom IncCOM · shares 0% · price −12.2%	4.5%	4.7%	$70.8M	1.0M	0%	$68.29	$77.74	−12.2%	−$9.8M
11	Verve Therapeutics IncCOM · shares 0% · price −19.0%	3.6%	4.1%	$56.4M	12.3M	0%	$4.57	$5.64	−19.0%	−$13.2M
12	Prime Medicine IncCOM · shares 0% · price −31.8%	1.9%	2.6%	$30.0M	15.1M	0%	$1.99	$2.92	−31.8%	−$14.0M
13	Maze Therapeutics IncCOM · shares New	1.7%	—	$26.6M	2.4M	New	$11.01	—	—	—
14	CrowdStrikeCL A · shares −83% · price +3.0%	1.7%	8.5%	$26.2M	74,230	−83%	$352.58	$342.16	+3.0%	+$773,476
15	Monte Rosa Therapeutics IncCOM · shares 0% · price −33.1%	0.43%	0.59%	$6.8M	1.5M	0%	$4.64	$6.94	−33.1%	−$3.4M
16	Oscar Health IncCL A · shares 0% · price −2.5%	0.40%	0.38%	$6.3M	481,988	0%	$13.11	$13.44	−2.5%	−$159,056
17	Beam Therapeutics IncCOM · shares 0% · price −21.2%	0.40%	0.46%	$6.3M	321,604	0%	$19.53	$24.80	−21.2%	−$1.7M
18	Vera Therapeutics IncCL A · shares 0% · price −43.2%	0.37%	0.59%	$5.8M	241,264	0%	$24.02	$42.29	−43.2%	−$4.4M
19	Desktop Metal IncCOM CL A · shares 0% · price +109.8%	0.34%	0.15%	$5.4M	1.1M	0%	$4.91	$2.34	+109.8%	+$2.8M
20	Sana Biotechnology IncCOM · shares 0% · price +3.1%	0.30%	0.27%	$4.7M	2.8M	0%	$1.68	$1.63	+3.1%	+$140,625
21	Relay Therapeutics IncCOM · shares 0% · price −36.4%	0.26%	0.38%	$4.1M	1.6M	0%	$2.62	$4.12	−36.4%	−$2.4M
22	Dianthus Therapeutics IncCOM · shares 0% · price −16.8%	0.24%	0.26%	$3.8M	208,697	0%	$18.14	$21.80	−16.8%	−$763,831
23	Lyell Immunopharma IncCOM · shares 0% · price −15.6%	0.20%	0.22%	$3.2M	5.9M	0%	$0.540	$0.640	−15.6%	−$586,512
24	Genedx Holdings CorpCOM · shares 0% · price +15.2%	0.13%	0.10%	$2.0M	22,711	0%	$88.57	$76.86	+15.2%	+$265,946
25	Foghorn Therapeutics IncCOM · shares 0% · price −22.7%	0.12%	0.14%	$1.8M	500,901	0%	$3.65	$4.72	−22.7%	−$535,964
	Total · 40 positions	100%		$1.58B						−$193.9M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q4 2024 to Q1 2025: 37 stocks held throughout, down $193.9M (−13.8%).

Tempus AI+$22.5M+43%
Desktop Metal Inc+$2.8M+110%
CrowdStrike+$773,476+3%
Genedx Holdings Corp+$265,946+15%
Sana Biotechnology Inc+$140,625+3%
Planet Labs Pbc−$21.1M−16%
Gitlab Inc−$25.5M−17%
Arm Holdings Plc−$32.5M−13%
Freshworks Inc−$33.4M−13%
Revolution Medicines Inc−$34.6M−19%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗